Cargando…

Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity

The taxane family of compounds, including Taxol/paclitaxel and Taxotere/docetaxel, are surprisingly successful drugs used in combination or alone for the treatment of most major solid tumors, especially metastatic cancer. The drugs are commonly used in regimen with other agents (often platinum drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaya, Celina, Smith, Elizabeth R., Xu, Xiang-Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066212/
https://www.ncbi.nlm.nih.gov/pubmed/35517405
http://dx.doi.org/10.7150/jca.71263
_version_ 1784699758049230848
author Amaya, Celina
Smith, Elizabeth R.
Xu, Xiang-Xi
author_facet Amaya, Celina
Smith, Elizabeth R.
Xu, Xiang-Xi
author_sort Amaya, Celina
collection PubMed
description The taxane family of compounds, including Taxol/paclitaxel and Taxotere/docetaxel, are surprisingly successful drugs used in combination or alone for the treatment of most major solid tumors, especially metastatic cancer. The drugs are commonly used in regimen with other agents (often platinum drugs) as frontline treatment, or used as a single agent in a dose dense regimen for recurrent cancer. The major side effects of taxanes are peripheral neuropathy, alopecia, and neutropenia, which are grave burden for patients and limit the full potential of the taxane drugs. Especially in the current treatment protocol for peripheral neuropathy, taxane dosage is reduced once the symptoms present, resulting in the loss of full or optimal cancer killing activity. Substantial efforts have been made to address the problem of cytotoxic side effects of taxanes, though strategies remain very limited. Following administration of the taxane compound by infusion, taxane binds to cellular microtubules and is sequestered within the cells for several days. Taxane stabilizes and interferes with microtubule function, leading to ultimate death of cancer cells, but also damages hair follicles, peripheral neurons, and hemopoietic stem cells. Currently, cryo-treatment is practiced to limit exposure and side effects of the drug during infusion, though the effectiveness is uncertain or limited. A recent laboratory finding may provide a new strategy to counter taxane cytotoxicity, that a brief exposure to low density ultrasound waves was sufficient to eliminate paclitaxel cytotoxicity cells in culture by transiently breaking microtubule filaments, which were then relocated to lysosomes for disposal. Thus, ultrasonic force to break rigid microtubules is an effective solution to counter taxane cytotoxicity. The discovery and concept of low intensity ultrasound as an antidote may have the potential to provide a practical strategy to counter paclitaxel-induced peripheral neuropathy and alopecia that resulted from chemotherapy. Taxanes are a class of important drugs used in chemotherapy to treat several major cancers. This article reviews a new laboratory discovery that ultrasound can be used as an antidote for the peripheral cytotoxicity of taxane drugs and discusses the potential development and application of low intensity ultrasound to prevent side effects in chemotherapeutic treatment of cancer patients.
format Online
Article
Text
id pubmed-9066212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-90662122022-05-04 Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity Amaya, Celina Smith, Elizabeth R. Xu, Xiang-Xi J Cancer Review The taxane family of compounds, including Taxol/paclitaxel and Taxotere/docetaxel, are surprisingly successful drugs used in combination or alone for the treatment of most major solid tumors, especially metastatic cancer. The drugs are commonly used in regimen with other agents (often platinum drugs) as frontline treatment, or used as a single agent in a dose dense regimen for recurrent cancer. The major side effects of taxanes are peripheral neuropathy, alopecia, and neutropenia, which are grave burden for patients and limit the full potential of the taxane drugs. Especially in the current treatment protocol for peripheral neuropathy, taxane dosage is reduced once the symptoms present, resulting in the loss of full or optimal cancer killing activity. Substantial efforts have been made to address the problem of cytotoxic side effects of taxanes, though strategies remain very limited. Following administration of the taxane compound by infusion, taxane binds to cellular microtubules and is sequestered within the cells for several days. Taxane stabilizes and interferes with microtubule function, leading to ultimate death of cancer cells, but also damages hair follicles, peripheral neurons, and hemopoietic stem cells. Currently, cryo-treatment is practiced to limit exposure and side effects of the drug during infusion, though the effectiveness is uncertain or limited. A recent laboratory finding may provide a new strategy to counter taxane cytotoxicity, that a brief exposure to low density ultrasound waves was sufficient to eliminate paclitaxel cytotoxicity cells in culture by transiently breaking microtubule filaments, which were then relocated to lysosomes for disposal. Thus, ultrasonic force to break rigid microtubules is an effective solution to counter taxane cytotoxicity. The discovery and concept of low intensity ultrasound as an antidote may have the potential to provide a practical strategy to counter paclitaxel-induced peripheral neuropathy and alopecia that resulted from chemotherapy. Taxanes are a class of important drugs used in chemotherapy to treat several major cancers. This article reviews a new laboratory discovery that ultrasound can be used as an antidote for the peripheral cytotoxicity of taxane drugs and discusses the potential development and application of low intensity ultrasound to prevent side effects in chemotherapeutic treatment of cancer patients. Ivyspring International Publisher 2022-04-18 /pmc/articles/PMC9066212/ /pubmed/35517405 http://dx.doi.org/10.7150/jca.71263 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Amaya, Celina
Smith, Elizabeth R.
Xu, Xiang-Xi
Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title_full Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title_fullStr Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title_full_unstemmed Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title_short Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
title_sort low intensity ultrasound as an antidote to taxane/paclitaxel-induced cytotoxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066212/
https://www.ncbi.nlm.nih.gov/pubmed/35517405
http://dx.doi.org/10.7150/jca.71263
work_keys_str_mv AT amayacelina lowintensityultrasoundasanantidotetotaxanepaclitaxelinducedcytotoxicity
AT smithelizabethr lowintensityultrasoundasanantidotetotaxanepaclitaxelinducedcytotoxicity
AT xuxiangxi lowintensityultrasoundasanantidotetotaxanepaclitaxelinducedcytotoxicity